Citation
Gubelin Harcha, Walter, et al. "A Randomized, Active- and Placebo-controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia." Journal of the American Academy of Dermatology, vol. 70, no. 3, 2014, pp. 489-498.e3.
Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498.e3.
Gubelin Harcha, W., Barboza Martínez, J., Tsai, T. F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Journal of the American Academy of Dermatology, 70(3), 489-e3. https://doi.org/10.1016/j.jaad.2013.10.049
Gubelin Harcha W, et al. A Randomized, Active- and Placebo-controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia. J Am Acad Dermatol. 2014;70(3):489-498.e3. PubMed PMID: 24411083.
TY - JOUR
T1 - A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
AU - Gubelin Harcha,Walter,
AU - Barboza Martínez,Julia,
AU - Tsai,Tsen-Fang,
AU - Katsuoka,Kensei,
AU - Kawashima,Makoto,
AU - Tsuboi,Ryoji,
AU - Barnes,Allison,
AU - Ferron-Brady,Geraldine,
AU - Chetty,Dushen,
Y1 - 2014/01/09/
PY - 2013/07/15/received
PY - 2013/10/24/revised
PY - 2013/10/27/accepted
PY - 2014/1/14/entrez
PY - 2014/1/15/pubmed
PY - 2014/4/12/medline
KW - 5-alpha reductase
KW - 5-alpha reductase inhibitors
KW - androgenetic alopecia
KW - dutasteride
KW - finasteride
KW - male pattern baldness
KW - male pattern hair loss
KW - treatment
SP - 489
EP - 498.e3
JF - Journal of the American Academy of Dermatology
JO - J Am Acad Dermatol
VL - 70
IS - 3
N2 - BACKGROUND: Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment. OBJECTIVE: We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha reductase inhibitor) and placebo in men with androgenetic alopecia. METHODS: Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes. RESULTS: In total, 917 men were randomized. Hair count and width increased dose dependently with dutasteride. Dutasteride 0.5 mg significantly increased hair count and width in a 2.54-cm diameter and improved hair growth (frontal view; panel photographic assessment) at week 24 compared with finasteride (P = .003, P = .004, and P = .002, respectively) and placebo (all P < .001). The number and severity of adverse events were similar among treatment groups. LIMITATIONS: The study was limited to 24 weeks. CONCLUSIONS: Dutasteride increased hair growth and restoration in men with androgenetic alopecia and was relatively well tolerated.
SN - 1097-6787
UR - https://www.unboundmedicine.com/medline/citation/24411083/A_randomized_active__and_placebo_controlled_study_of_the_efficacy_and_safety_of_different_doses_of_dutasteride_versus_placebo_and_finasteride_in_the_treatment_of_male_subjects_with_androgenetic_alopecia_
DB - PRIME
DP - Unbound Medicine
ER -
